CCM
BBIO icon

Coldstream Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Coldstream Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Buy
4,898
+698
+17% +$48.9K ﹤0.01% 884
2026
Q1 		$312K Buy
4,200
+1,029
+32% +$74.6K ﹤0.01% 914
2025
Q4 		$243K Buy
+3,171
New +$208K ﹤0.01% 1009
2025
Q2 		– Sell
-965
Closed -$33.4K – 1346
2025
Q1 		$33.4K Buy
+965
New +$32.5K ﹤0.01% 1888

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Coldstream Capital Management's BBIO Position: Q2 2026 in Review

Coldstream Capital Management increased its BridgeBio Pharma (BBIO) stake by 17% in Q2 2026, buying an estimated $48.9K and bringing the position to 4,898 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #884.

Coldstream Capital Management first reported a position in BBIO in Q1 2025 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Coldstream Capital Management held 4,898 shares of BridgeBio Pharma worth $365K as of Q2 2026.
  • Coldstream Capital Management bought 698 BridgeBio Pharma shares in Q2 2026, an estimated $48.9K.
  • BridgeBio Pharma made up ﹤0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #884 holding.
  • Coldstream Capital Management first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 4 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.